What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?
- 138 Downloads
Atrial fibrillation (AF) is becoming increasingly common in an ageing population. Much of the morbidity and mortality in AF is due to stroke and thromboembolism. Awareness of stroke risk and the need for prevention is well recognized but is far from satisfactory in the real world. Despite refinements in the risk stratification over the years, there is an unmet need for appropriate thromboprophylaxis due to the underuse of oral anticoagulation. Primary care physicians and generalists bear the burden of managing AF. Coordinated multidisciplinary efforts by cardiologists, primary care physicians, and neurologists may be needed to meet the increasing challenge of stroke prevention and rhythm management in AF. This article discusses the potential the role of the cardiologist in the management of stroke prevention in patients with AF.
Keywordsanticoagulants atrial fibrillation cardiologist risk stratification stroke thromboprophylaxis
Unable to display preview. Download preview PDF.
- 27.Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1–5.Google Scholar
- 30.Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765–1769.Google Scholar
- 32.Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;10:373:155–166.Google Scholar
- 33.Williams E, Ansari M, Lip G. Managing atrial fibrillation in the accident and emergency department. Quart J Med. 2001;94:609–614.Google Scholar
- 36.European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–1420.PubMedCrossRefGoogle Scholar
- 42.Fitzmaurice DA. The NICE guidelines on atrial fibrillation: a personal view. Br J Cardiol. 2007:14:29–30.Google Scholar
- 50.Connolly S, Eikelboom J, Flaker G, et al. AVERROES: apixaban versus acetyl salicyclic acid to prevent strokes. Presented at: European Society of Cardiology; August 31, 2010; Stockholm, Sweden.Google Scholar
- 54.Bonow RO, Carabello B, Chatterjee K, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2006;114:e84–231.Google Scholar
- 56.Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009;374:534–542.Google Scholar
- 57.Hughes M, Lip GY, on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation related bleeding complications in patients with atrial fibrillation: a systematic review. Q J Med. 2007;100:599–607.Google Scholar